72.53

0.05% 0.035

Bio Techne Corp (TECH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Bio Techne Corp stock is traded at $72.53, with a volume of 1.55M. It is up +0.05% in the last 24 hours and up +0.27% over the past month. Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Previous Close:

$72.50

Open:

$72.53

24h Volume:

1.55M

Relative Volume:

0.58

Market Cap:

$11.37B

Revenue:

$1.21B

Net Income/Loss:

$109.52M

P/E Ratio:

104.19

EPS:

0.6962

Net Cash Flow:

$269.60M

1W Performance:

+0.12%

1M Performance:

+0.27%

6M Performance:

+24.01%

1Y Performance:

+21.74%

1-Day Range:

$72.50

$72.61

1-Week Range:

$72.44

$72.58

52-Week Range:

$43.20

$72.69

Bio Techne Corp Stock (TECH) Company Profile

Name

Bio Techne Corp

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

612-379-8854

Address

614 MCKINLEY PL N E, MINNEAPOLIS, MN

Employee

3,000

Twitter

@biotechne

Next Earnings Date

2026-11-04

Latest SEC Filings

TECH's Discussions on Twitter

Compare TECH vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TECH Bio Techne Corp	72.53	11.37B	1.21B	109.52M	269.60M	0.6962
VRTX Vertex Pharmaceuticals Inc	510.73	129.45B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	238.50	95.22B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	805.62	82.94B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	848.35	53.35B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	371.62	42.04B	5.76B	514.49M	1.10B	4.4813

Bio Techne Corp Stock (TECH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-13-26	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-11-26	Initiated	Piper Sandler	Neutral
May-15-26	Resumed	RBC Capital Mkts	Outperform
Sep-03-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Aug-21-25	Upgrade	Citigroup	Neutral → Buy
Jul-22-25	Resumed	Stephens	Overweight
Jul-09-25	Initiated	TD Cowen	Buy
May-30-25	Initiated	Wells Fargo	Overweight
Apr-09-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Mar-18-25	Initiated	Evercore ISI	Outperform
Feb-19-25	Downgrade	Robert W. Baird	Outperform → Neutral
May-22-24	Downgrade	Citigroup	Buy → Neutral
Feb-08-24	Initiated	Scotiabank	Sector Outperform
Feb-02-24	Downgrade	Stifel	Buy → Hold
Dec-07-23	Initiated	UBS	Buy
Aug-28-23	Initiated	William Blair	Outperform
Jan-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform
Aug-25-22	Initiated	Credit Suisse	Outperform
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight
Sep-15-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-08-21	Upgrade	Stephens	Equal-Weight → Overweight
Feb-23-21	Upgrade	Stifel	Hold → Buy
Jan-25-21	Reiterated	The Benchmark Company	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-30-20	Initiated	Atlantic Equities	Overweight
Jul-15-20	Downgrade	Stephens	Overweight → Equal-Weight
May-27-20	Downgrade	Stifel	Buy → Hold
May-14-20	Initiated	The Benchmark Company	Buy
Jan-08-20	Resumed	Stephens	Overweight
Jan-08-20	Initiated	Wells Fargo	Equal Weight
Jan-07-20	Initiated	Citigroup	Neutral
Nov-15-19	Initiated	Stifel	Buy
Jul-02-19	Upgrade	Janney	Neutral → Buy
Jan-14-19	Upgrade	Stephens	Equal-Weight → Overweight
Oct-31-18	Downgrade	Craig Hallum	Buy → Hold
Oct-17-18	Initiated	Goldman	Neutral
Jun-15-18	Initiated	Argus	Buy
Jul-13-17	Initiated	Wells Fargo	Market Perform
Feb-09-17	Initiated	Citigroup	Buy
Jan-18-17	Initiated	Deutsche Bank	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Jan-21-15	Reiterated	Robert W. Baird	Outperform
Sep-20-13	Upgrade	Robert W. Baird	Neutral → Outperform

View All

Bio Techne Corp Stock (TECH) Latest News

Oct 08, 2026

Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development - Investing News Network

Oct 08, 2026

Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development - Yahoo Finance

Oct 08, 2026

Oct 07, 2026

Bio-Techne Company Profile & Introduction - Moomoo

Oct 07, 2026

Sep 30, 2026

INCY or TECH: Which Is the Better Value Stock Right Now? - Zacks Investment Research

Sep 30, 2026

Sep 25, 2026

Robert V Baumgartner Exercises Options, Realizes $754KBio-Techne (NASDAQ:TECH) - Benzinga

Sep 25, 2026

Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package - Yahoo Finance

Sep 25, 2026

Sep 24, 2026

Bio-Techne (TECH) director exercises options and delivers or withholds 5,559 shares for costs or taxes. - Stock Titan

Sep 24, 2026

Bio-Techne shareholders approve $11.3 billion merger with German Merck - AKM.RU

Sep 24, 2026

What Does Shareholder Approval Mean for Bio-Techne's (NASDAQ:TECH) Merck KGaA Deal? - Kalkine Media

Sep 24, 2026

Is Bio-Techne Stock Outperforming the Nasdaq? - finance.yahoo.com

Sep 24, 2026

Is Bio-Techne Stock Outperforming the Nasdaq? - barchart.com

Sep 24, 2026

Sep 23, 2026

Form 8K Bio-Techne Corp For: 23 September By Investing.com - Investing.com Canada

Sep 23, 2026

Form 8K Bio-Techne Corp For: 23 September - Investing.com India

Sep 23, 2026

Merck KGaA's USD 11.3b Bio-Techne acquisition clears final shareholder approval hurdle - AllSci

Sep 23, 2026

Bio-Techne (TECH) Opens Düsseldorf Hub As Fair Value Questions Come Into Focus - simplywall.st

Sep 23, 2026

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany - Investing News Network

Sep 23, 2026

Bio-Techne shareholders approve Merck KGaA acquisition - Investing.com

Sep 23, 2026

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany - PR Newswire

Sep 23, 2026

Sep 22, 2026

Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration - marketscreener.com

Sep 22, 2026

Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration - Yahoo Finance

Sep 22, 2026

Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration - Investing News Network

Sep 22, 2026

Sep 21, 2026